Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer (TJSPAC-03)

12 listopada 2026 zaktualizowane przez: Chuntao Gao, Tianjin Medical University Cancer Institute and Hospital

A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Concurrent Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer (TJSPAC-03)

This is a Phase I/II, single-arm, open-label, exploratory study aimed at evaluating the safety, tolerability, and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with gemcitabine and iparomlimab-toripalimab in patients with borderline resectable pancreatic cancer. The study is divided into two phases: The Phase Ib dose-escalation phase will use a "3+3" design to explore the maximum tolerated dose (MTD) of SBRT (6 Gy×5 F, 7 Gy×5 F, 8 Gy×5 F) combined with gemcitabine and iparomlimab-toripalimab. The Phase II phase will further evaluate the efficacy and safety of this combination regimen based on the SBRT dose determined in Phase Ib. The primary efficacy endpoint is the R0 resection rate.

Przegląd badań

Szczegółowy opis

This is a single-center, Phase I/II, single-arm, open-label, exploratory clinical study initiated by Tianjin Medical University Cancer Institute & Hospital.

Phase Ib (Dose-Escalation Phase): A classic "3+3" design will be used to explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of SBRT. Three pre-specified SBRT dose levels are planned: 6 Gy×5 F, 7 Gy×5 F, and 8 Gy×5 F. All subjects will concurrently receive standard-dose gemcitabine chemotherapy and iparomlimab-toripalimab immunotherapy. The DLT observation period is 6 months from the start of treatment, focusing on Grade 3 or higher SBRT-related toxicities in organs at risk. The MTD is defined as the highest dose level at which ≤33% (i.e., no more than 1 out of 6) of subjects experience a DLT during the observation period.

Phase II (Expansion Phase): Based on the SBRT MTD determined in Phase Ib, preoperative neoadjuvant therapy will be administered in combination with gemcitabine and iparomlimab-toripalimab. The treatment cycle consists of 3 cycles, expected to last 12 weeks. Tumor assessment will be performed after 2 cycles of treatment. If there is no disease progression and adverse reactions are tolerable, treatment will continue. Surgical resection will be performed 3-4 weeks after the last dose of chemotherapy and immunotherapy. Postoperatively, if the investigator determines the patient may benefit, adjuvant therapy will be administered, consisting of 4 cycles of gemcitabine chemotherapy and maintenance immunotherapy with iparomlimab-toripalimab for up to 1 year. The primary endpoint is the R0 resection rate.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

30

Faza

  • Faza 2
  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

  • Nazwa: Maobin Meng(Co-Principal Investigator), PhD
  • Numer telefonu: 15202231270
  • E-mail: mmeng@tmu.edu.cn

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Age ≥18 years and ≤75 years, both genders.
  2. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
  3. Radiographically assessed as borderline resectable pancreatic cancer according to NCCN guidelines.
  4. At least one measurable lesion per RECIST v1.1 criteria.
  5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  6. Adequate organ and bone marrow function.
  7. Expected survival ≥ 6 months.
  8. Voluntarily signed informed consent form.

Exclusion Criteria:

  1. Known distant metastases.
  2. Prior systemic anti-tumor therapy or radiotherapy for pancreatic cancer.
  3. Active autoimmune disease requiring systemic treatment within the past 2 years.
  4. History of other malignancies within the past 5 years, except for cured carcinoma in situ of the cervix, non-melanoma skin cancer, or superficial bladder tumor.
  5. Uncontrolled comorbid conditions, including but not limited to active infections, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  6. Pregnant or lactating women.
  7. Any condition that, in the investigator's opinion, would make the subject unsuitable for participation in the study.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Iparomlimab-Tuvonralimab + Gemcitabine Group

Participants will receive Iparomlimab-Tuvonralimab (10 mg/kg, IV, D1) combined with Gemcitabine (1000 mg/m², IV, D1 and D8) every 3 weeks for up to 6 cycles. After 6 cycles, participants without disease progression and with acceptable tolerance may continue to receive Iparomlimab-Tuvonralimab (10 mg/kg, IV, D1, every 3 weeks) as maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, or study termination.

Iparomlimab/Tuvonralimab (Code: QL1706) is a bispecific antibody targeting PD-1 and CTLA-4. It is administered by intravenous infusion at a dose of XX mg/kg once every 3 weeks until disease progression or unacceptable toxicity.

Gemcitabine (Brand name: Gemzar) is a nucleoside analogue chemotherapeutic agent. It is administered by intravenous infusion at a dose of 1000 mg/m² on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.

SBRT is a highly precise form of radiation therapy that delivers high doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues. It is administered in XX fractions over XX days/weeks.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Objective Response Rate, ORR
Ramy czasowe: From first dose to disease progression or study completion, up to approximately 24 months

Objective Response Rate assessed by RECIST v1.1, defined as the proportion of participants who achieve complete response (CR) or partial response (PR).

From first dose to disease progression or study completion, up to approximately 24 months
Incidence of Adverse Events
Ramy czasowe: From first dose to 90 days after last dose, up to approximately 27 months

Incidence and severity of adverse events assessed by CTCAE v5.0, including treatment-related adverse events (TRAEs), serious adverse events (SAEs), and immune-related adverse events (irAEs).

From first dose to 90 days after last dose, up to approximately 27 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Disease Control Rate, DCR
Ramy czasowe: From first dose to disease progression or study completion, up to approximately 24 months

Disease Control Rate assessed by RECIST v1.1, defined as the proportion of participants who achieve complete response (CR), partial response (PR), or stable disease (SD).

From first dose to disease progression or study completion, up to approximately 24 months
Progression-Free Survival, PFS
Ramy czasowe: From first dose to disease progression or death, up to approximately 24 months

Progression-Free Survival assessed by RECIST v1.1, defined as the time from first dose to the first documentation of disease progression or death from any cause.

From first dose to disease progression or death, up to approximately 24 months
Overall Survival, OS
Ramy czasowe: From first dose to death or last follow-up, up to approximately 36 months

Defined as the time from first dose to death from any cause.

From first dose to death or last follow-up, up to approximately 36 months
Duration of Response, DOR
Ramy czasowe: From first documentation of response to disease progression or death, up to approximately 24 months

Duration of Response assessed by RECIST v1.1, defined as the time from the first documentation of complete response (CR) or partial response (PR) to the first documentation of disease progression or death from any cause.

From first documentation of response to disease progression or death, up to approximately 24 months

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Correlation between Biomarkers and Clinical Efficacy
Ramy czasowe: From first dose to study completion, up to approximately 36 months

To explore the correlation between biomarkers such as PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI) status in tumor tissue and clinical efficacy endpoints including ORR, PFS, and OS.

From first dose to study completion, up to approximately 36 months
Quality of Life Assessment
Ramy czasowe: From baseline to 90 days after last dose, up to approximately 27 months

To evaluate changes in quality of life during and after treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).

From baseline to 90 days after last dose, up to approximately 27 months
Dynamic Changes of Peripheral Blood Immune Cell Subsets and Cytokines
Ramy czasowe: From first dose to disease progression or study completion, up to approximately 24 months

To explore the dynamic changes of peripheral blood immune cell subsets (CD3+, CD4+, CD8+ T cells, etc.) and cytokines (IL-6, TNF-α, IFN-γ, etc.) during treatment and their correlation with efficacy and adverse events.

From first dose to disease progression or study completion, up to approximately 24 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 grudnia 2026

Zakończenie podstawowe (Szacowany)

30 czerwca 2028

Ukończenie studiów (Szacowany)

20 lutego 2030

Daty rejestracji na studia

Pierwszy przesłany

12 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

12 listopada 2026

Pierwszy wysłany (Rzeczywisty)

18 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

12 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

This is a prospective, single-arm, single-center Phase II clinical study to evaluate the efficacy and safety of Iparomlimab/Tuvonralimab combined with gemcitabine in the treatment of locally advanced pancreatic cancer. The study plans to enroll 30 patients with histologically or cytologically confirmed locally advanced pancreatic ductal adenocarcinoma. Subjects will receive Iparomlimab/Tuvonralimab combined with gemcitabine until disease progression, intolerable toxicity, withdrawal of informed consent, or completion of 6 cycles of treatment. The primary endpoint is objective response rate (ORR), and secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj